A team of Russian researchers has synthesised a novel compound for boron neutron capture therapy (BNCT), a treatment for advanced cancer that uses the boron-10 isotope. The compound exhibits low toxicity, excellent water solubility, and eliminates the need for administering large volumes. Most importantly, the active substance reaches the tumour with minimal impact on healthy tissues. The study was published in the International Journal of Molecular Sciences shortly before World Cancer Day, observed annually on February
Boron neutron Scientists Develop capture therapy
(BNCT) is an advanced cancer treatment that leverages the properties of the boron-10 isotope. The method involves first saturating tumour cells with boron-10, learn german and go to germany? why not! followed by irradiation with thermal neutrons. This triggers a nuclear reaction that selectively destroys cancer cells while sparing healthy tissue. Thus, the treatment success largely depends on the compound’s ability to effectively deliver boron-10 to the tumour and maintain the necessary boron concentration.
A team of scientists from the HSE Faculty of Chemistry, the Institute of General and Inorganic Chemistry of the Russian Academy of Sciences, and the N.N. Blokhin 10 mistakes lawyers make when managing social networks National Medical Research Centre of Oncology has developed three compounds that combine the closo-dodecaborate anion with amino acids containing a side-chain amino group. The molecules are structurally similar to natural amino acids, allowing them to ‘trick’ the body’s transport systems into capturing and delivering them to cells, including cancer cells. This makes the substance effective at targeting tumours, where it accumulates.
One of the compounds demonstrated
low toxicity, with the half-lethal dose (LD50) for experimental animals ranging from 150 to 300 mg per kilogram of body weight. In experiments, the compound not only hindi directory demonstrated the ability to accumulate boron in tumour tissues but also confirmed its effectiveness in animals. When administered to laboratory mice, the boron concentration in melanoma tumour cells was six times higher than in healthy tissues after 45 minutes.